IWM
MYGN icon

IHT Wealth Management’s Myriad Genetics MYGN Stock Holding History

IHT Wealth Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-91
Closed -$2K – 1445
2017
Q1 		$2K Hold
91
– – ﹤0.01% 1088
2016
Q4 		$2K Buy
+91
New +$1.65K ﹤0.01% 1045

Other funds holding MYGN

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

IHT Wealth Management's MYGN Position: Q2 2017 in Review

IHT Wealth Management sold out of Myriad Genetics (MYGN) in Q2 2017, closing a stake of 91 shares — an estimated $2K sold.

IHT Wealth Management first reported a position in MYGN in Q4 2016 and held it in 2 quarters. The position peaked at $2K in Q1 2017. 239 funds tracked by Wall St. Rank hold MYGN as of Q2 2017.

  • IHT Wealth Management reported no remaining Myriad Genetics position as of Q2 2017 after selling out during the quarter.
  • IHT Wealth Management sold 91 Myriad Genetics shares in Q2 2017, an estimated $2K.
  • IHT Wealth Management first reported a position in Myriad Genetics in Q4 2016 and held it in 2 quarters.
  • IHT Wealth Management's Myriad Genetics position peaked at $2K in Q1 2017.
  • 239 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2017.

Based on IHT Wealth Management's 13F filing for Q2 2017, filed 14 Aug 2017.